Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use : a quasi-experimental study in a region of high MRSA prevalence
BACKGROUND: Despite vancomycin use is a major risk factor for the emergence of vancomycin resistance, it is frequently inappropriately prescribed, especially as empirical treatment. We evaluated the effect of an antimicrobial stewardship intervention targeting for inappropriate continued empirical vancomycin use.
METHODS: This was a quasi-experimental study comparing vancomycin use in a 6-month pre-intervention and 6-month intervention period. If empirical vancomycin was continued for more than 96 h without documentation of beta-lactam-resistant gram-positive microorganisms, it was considered inappropriate continued empirical vancomycin use. The intervention consisted of the monitoring of appropriateness by a pharmacist and direct discussion with the prescribing physicians by infectious disease specialists when empirical vancomycin was continued inappropriately. An interrupted time series analysis was used to compare vancomycin use before and during the intervention.
RESULTS: Following implementation of the intervention, overall vancomycin consumption decreased by 14.6%, from 37.6 defined daily doses (DDDs)/1000 patient-days in the pre-intervention period to 32.1 DDDs/1000 patient-days in the intervention period (P < 0.001). The inappropriate consumption of vancomycin also declined from 8.0 DDDs/1000 patient-days to 5.8 DDDs/1000 patient-days (P = 0.009).
CONCLUSION: Interventions such as direct communication with prescribing physicians and infectious disease clinicians can help reduce the inappropriate continued use of vancomycin.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 18(2018), 1 vom: 16. Apr., Seite 178 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Choe, Pyoeng Gyun [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6Q205EH1VU |
|---|
| Anmerkungen: |
Date Completed 10.06.2019 Date Revised 13.06.2019 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-018-3081-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM283095032 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM283095032 | ||
| 003 | DE-627 | ||
| 005 | 20231225035623.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-018-3081-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0943.xml |
| 035 | |a (DE-627)NLM283095032 | ||
| 035 | |a (NLM)29661158 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Choe, Pyoeng Gyun |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of an intervention targeting inappropriate continued empirical parenteral vancomycin use |b a quasi-experimental study in a region of high MRSA prevalence |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.06.2019 | ||
| 500 | |a Date Revised 13.06.2019 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Despite vancomycin use is a major risk factor for the emergence of vancomycin resistance, it is frequently inappropriately prescribed, especially as empirical treatment. We evaluated the effect of an antimicrobial stewardship intervention targeting for inappropriate continued empirical vancomycin use | ||
| 520 | |a METHODS: This was a quasi-experimental study comparing vancomycin use in a 6-month pre-intervention and 6-month intervention period. If empirical vancomycin was continued for more than 96 h without documentation of beta-lactam-resistant gram-positive microorganisms, it was considered inappropriate continued empirical vancomycin use. The intervention consisted of the monitoring of appropriateness by a pharmacist and direct discussion with the prescribing physicians by infectious disease specialists when empirical vancomycin was continued inappropriately. An interrupted time series analysis was used to compare vancomycin use before and during the intervention | ||
| 520 | |a RESULTS: Following implementation of the intervention, overall vancomycin consumption decreased by 14.6%, from 37.6 defined daily doses (DDDs)/1000 patient-days in the pre-intervention period to 32.1 DDDs/1000 patient-days in the intervention period (P < 0.001). The inappropriate consumption of vancomycin also declined from 8.0 DDDs/1000 patient-days to 5.8 DDDs/1000 patient-days (P = 0.009) | ||
| 520 | |a CONCLUSION: Interventions such as direct communication with prescribing physicians and infectious disease clinicians can help reduce the inappropriate continued use of vancomycin | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Antimicrobial stewardship | |
| 650 | 4 | |a Inappropriate use | |
| 650 | 4 | |a Infectious disease specialist | |
| 650 | 4 | |a Intervention | |
| 650 | 4 | |a Pharmacist | |
| 650 | 4 | |a Vancomycin | |
| 650 | 7 | |a Anti-Bacterial Agents |2 NLM | |
| 650 | 7 | |a Vancomycin |2 NLM | |
| 650 | 7 | |a 6Q205EH1VU |2 NLM | |
| 700 | 1 | |a Koo, Hei Lim |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, Doran |e verfasserin |4 aut | |
| 700 | 1 | |a Bae, Ji Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Eunyoung |e verfasserin |4 aut | |
| 700 | 1 | |a Hwang, Joo-Hee |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Kyoung-Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Wan Beom |e verfasserin |4 aut | |
| 700 | 1 | |a Bang, Ji Hwan |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Eu Suk |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Hong Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sang Won |e verfasserin |4 aut | |
| 700 | 1 | |a Oh, Myoung-Don |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Nam Joong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 18(2018), 1 vom: 16. Apr., Seite 178 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2018 |g number:1 |g day:16 |g month:04 |g pages:178 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-018-3081-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2018 |e 1 |b 16 |c 04 |h 178 | ||